Lilly Splurges $3.8B On Three Vaccine Companies, Dipping Its Proverbial Pen Into Infectious Diseases

Ashtray money bro… 

Eli Lilly is back on its BS the drugmaker said Tuesday it's backing up the brinks truck on Curevo (shingles), LimmaTech Biologics (the clap), and Vaccine Company (how original) for up to $3.8 billion combined. Bigly. For context, this now marks Lilly's official re-entry into infectious disease and gives it pipelines for shingles, bacterial pathogens, and Epstein-Barr Virus.

In short, with the war chest of Mounjaro and Zepbound cash to match… management has been methodically deploying that obesity money into every other corner of pharma: cancer drugs, Alzheimer's, immunology, and as of Tuesday, vaccines for shingles, staph, the clap, chlamydia, and EBV. The GLP-1 cash machine has a research budget attached, and the dry powder is now writing nine-figure checks during premarket. 

The first fat check, $1.5 billion, goes to Curevo and its shingles vaccine, amezosvatein (don’t worry, I can’t pronounce it either). This is a BFD, because in a Phase 2 head-to-head against GSK's Shingrix, amezosvatein matched the immune response and cut chills, fatigue, and injection-site pain by more than half. Spoiler: Curevo is eating Shingrix's lunch on tolerability. GSK has had the shingles market to itself for eight years on no competition; that floor just got real noisy. Additionally, Curevo also gets to ride the increasingly serious "shingles vaccine cuts dementia risk" research wave, which is the rare longevity headline your MAGA aunt and your wellness girlfriend agree on.

Over in the LimmaTech Biologics corner, they get $780 million to take a swing at the pathogens antibiotics are slowly losing to. Staph aureus, gonorrhea, chlamydia. The kind of bacteria your med-school friend warned you about when you told them about your weekend in 2008. LimmaTech's lead is a Phase 1 staph vaccine, and the preclinical pipeline targets the long-tail consequences of bacterial infection that, per the press release, "fall disproportionately on women." Plain English: female fertility damage from untreated infections, which, you know, is one helluva public-health problem antibiotics used to handle until they stopped working.

Finally, we have the Vaccine Company. Lilly is paying up to $1.55 billion for a Phase 1-ready biotech that named itself, in the year 2026, after what it makes. The naming workshop ran, generously, four minutes. Of course, the science is real. In Vivo Nanoparticle tech, a five-antigen Epstein-Barr Virus candidate, an EBV-to-MS-and-cancer prevention thesis. Translation: It’s basically Temu Pfizer. 

Aaaaand, that’s all the checkbook wrote… for now. In the end, Lilly is going balls to the wall to leverage their weight loss cash cow to up the ante on an infectious disease pipeline. To which I say, if you got it smoke spend it. Of course, we’ll see what comes of this as more details come out, but in the meantime, keep your eyes open on that premarket action and place your bets accordingly. Until next time, friends… 

At the time of publishing, Stocks.News does not hold positions in companies mentioned in the article.